Chemo Spain – Leandro Sigman, General Manager
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
Established over 35 years ago, Chemo operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, both for human and animal health.
While the main offices are located in Madrid, Lugano and Buenos Aires, Chemo is acting worldwide, creating a broad and balanced manufacturing and commercial network across major pharmaceutical markets in Europe, America, Asia and Africa, to address global opportunities and customers` needs.
Chemo`s activity is organized in three synergistic business areas: industrial, branded and biotech, with over 5,000 professionals in more than 40 countries, across four continents, ten state-of-the-art manufacturing facilities, nine specialized R&D centers, 12 commercial offices and 33 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.
Chemo believes in innovation and sustainable development. The company’s commitment is to improve people`s health and quality of life, providing access to safe, quality and affordable medicines, and to continuously expand its efforts and R&D investment to develop new and better therapies.
Contact details:
Chemo Barcelona
Gran Vía Carlos III, 98 7th floor
08028 Barcelona , Spain.
Tel: + 34 93 330 62 12
Fax: + 34 93 330 27 62
BarcelonaChemo@chemogroup.com
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
Having moved early on a promising phase II monoclonal antibody, Almirall is inching closer to entering the Sanofi-dominated European market for eczema after posting, along with Eli Lilly, positive phase…
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
ADL Biopharma is a Spanish CDMO and, according to its CEO, owner of Europe’s largest fermenter. Ignacio Urbelz, CEO, reveals how, after a tumultuous time that saw the company go…
Way before securing the CEO role at Esteve in 2018, Staffan Schüberg built a career that saw him rise through the ranks of Lundbeck, from commercial activities in Sweden to…
Ignacio Vega, CEO of Cardiva and Cardivais, a Spanish medtech producer and distributor, explains how, as a manufacturer of PPE, the company had to reconfigure its production operations to supply…
Esteve’s CEO outlines the transformation journey of the Spanish company after taking over in 2018, commenting on how the divestment of its generics business has helped the company lay the…
Teva’s general manager for Spain and Portugal, Juan Carlos Conde Ibarra, dives into the recently announced strategy for the affiliate, including the move to a single brand in generics, and…
Margarita Alfonsel, general secretary of Fenin, the Spanish Federation of Healthcare Technology Companies, reflects on the COVID-19 pandemic, the changing dynamics of the medical technology industry in Spain, and comments…
AseBio is the association promoting the development of the Spanish biotechnology industry. Its general manager, Ion Arocena, lays out the main priorities for the country’s sector, including the need to…
Kern Pharma’s chairman and Grupo Indukern CEO, Raúl Díaz-Varela, explains the new strategic direction of the Spanish generics player, how their partnership with Celltrion to commercialise biosimilars has evolved, and…
HIPRA is a world-leading animal health company that has launched a record 22 animal vaccines in the last 10 years. During the COVID-19 pandemic, the European company decided to jump…
The Vall d’Hebron Institute of Oncology (VHIO) is a Barcelona-based institute dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments…
See our Cookie Privacy Policy Here
